CSIMarket Company Name, Ticker, Competitors, else..
 
Ironwood Pharmaceuticals inc   (IRWD)
Other Ticker:  
 
 
Price: $9.6000 $-0.01 -0.104%
Day's High: $9.645 Week Perf: 0.95 %
Day's Low: $ 9.41 30 Day Perf: 6.43 %
Volume (M): 1,386 52 Wk High: $ 12.66
Volume (M$): $ 13,302 52 Wk Avg: $10.53
Open: $9.55 52 Wk Low: $8.08



 Market Capitalization (Millions $) 1,794
 Shares Outstanding (Millions) 187
 Employees 970
 Revenues (TTM) (Millions $) 432
 Net Income (TTM) (Millions $) -981
 Cash Flow (TTM) (Millions $) -464
 Capital Exp. (TTM) (Millions $) 0

Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals Inc. is an American pharmaceutical company, founded in 1998, and is headquartered in Cambridge, Massachusetts. The company specializes in the development and commercialization of drugs to treat gastrointestinal disorders, including irritable bowel syndrome, acid reflux, and refractory gastroesophageal reflux disease.

Ironwood Pharmaceuticals Inc. has a broad range of products that are used in the treatment of gastrointestinal disorders, including medications like Linzess, Zelnorm, and Zurampic. Ironwood's lead product, Linzess, is approved by the FDA for the treatment of both irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). It works by regulating the activity of specific receptors in the gut, improving motility and reducing pain.

Ironwood Pharmaceuticals Inc. is committed to developing innovative solutions for gastrointestinal disorders. As such, it is actively involved in the research and clinical development of potential new treatments to address unmet medical needs. In 2014, Ironwood Pharmaceuticals Inc. entered into a strategic collaboration with AstraZeneca to develop and commercialize lesinurad, a potential treatment for gout.

Ironwood Pharmaceuticals Inc. has a dedicated team of over 500 employees who work together to advance the company's vision of transforming the treatment of gastrointestinal disorders. The company has a history of investing in research and development, and as of 2021, had over 150 patents and patent applications in the United States.

Ironwood Pharmaceuticals Inc. is also committed to giving back to the community. In 2020, the company announced a donation of $1 million to support organizations working to address racial injustice and health disparities in the United States.

In conclusion, Ironwood Pharmaceuticals Inc. is a pharmaceutical company focused on developing treatments for gastrointestinal disorders. With a broad range of products, a strong portfolio of patents, and a commitment to innovation and community engagement, Ironwood Pharmaceuticals Inc. is well-positioned to make a positive impact on the lives of patients with gastrointestinal disorders.


   Company Address: 100 Summer Street Boston 2110 MA
   Company Phone Number: 621-7722   Stock Exchange / Ticker: NASDAQ IRWD
   IRWD is expected to report next financial results on February 15, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals Inc Overcomes Revenue Setback, Prepares for Resurgence in Q4 2023

Enanta Pharmaceuticals Inc, a clinical-stage biotechnology company focused on developing small molecule drugs for viral infections, recently announced its financial results for the July to September 30, 2023, period. During this period, the company reported an increase in losses, which expanded from $1.27 per share a year prior to $1.32 per share. However, it is worth noting that the earnings per share (EPS) improved from -$1.86 in the preceding reporting period.
The revenue for the same period decreased by 6.817% to $18.93 million compared to $20.32 million in the previous reporting period. While sequentially, the revenue advanced slightly by 0.212% from $18.89 million. This decline in revenue could raise concerns, as it may indicate slowing demand for Enanta Pharmaceuticals Inc's products.
Procyon Corporation

Procyon Corporation Steams Ahead, Consolidating Revenue at PCYN in Record-breaking Quarter

Based on the financial time-frame ending September 30, 2023, Procyon Corporation has experienced significant declines and challenges, leading to a bearish outlook for the company. Depleting orders have played a crucial role in the losses incurred during this period.
The revenue for Procyon Corporation fell by -0.221% to $1.17 million compared to the previous reporting season, where revenue decreased by -2.42% from $1.20 million. This downward trend indicates a constant struggle for the company to maintain a steady revenue stream. It is clear that Procyon Corporation has been facing difficulties in generating consistent income.
China Health Industries Holdings Inc

Impressive 11.069% Revenue Surge Demonstrates China Health Industries Holdings Inc's Strong Growth Potential in Q3 2023



China Health Industries Holdings Inc (CHHE) recently announced its financial results for the fiscal period ending September 30, 2023. These results demonstrate the company's ability to achieve top-line growth despite industry-wide revenue reductions. Additionally, CHHE's inventories have declined, indicating potential future demand. This article will outline the facts and set the current financial results into context.
Financial Results Overview:
For the fiscal period ending September 30, 2023, CHHE reported a zero gain of $0.00 per share, compared to a loss of $0.01 per share during the same period a year ago. Sequentially, CHHE improved from a loss of $0.01 per share in the previous quarter. This indicates progress in generating profits and more favorable financial performance.
Acer Therapeutics Inc

Acer Therapeutics Inc Reports Revenue of $0.37179 Million in Q3 2023 Financial Report amidst Concerns of Declining Stock Performance



The stock performance of a company plays a vital role in determining its overall financial health. Acer Therapeutics Inc, a major player in the pharmaceutical preparations industry, has experienced a decline in its stock price over the past week, negatively impacting its year-to-date performance. This article aims to provide an overview of the recent trends seen in Acer Therapeutics Inc's stock performance, along with insights into the company's financial records and future expectations.
Stock Performance
Over the past week, Acer Therapeutics Inc's stock has experienced a decline, although the exact percentage decrease is undisclosed in the provided information. This downtrend has brought the company's year-to-date performance to a staggering -74.81%. Consequently, investors may have concerns about the company's financial stability, prompting a closer examination of its financial records.
Baudax Bio Inc

Baudax Bio Inc's Revenue Shows Steady Comparison to Previous Year During July-September 2023 Period



Baudax Bio Inc, a pharmaceutical company listed on the NASDAQ, recently released its financial results for the July to September 2023 period. The company demonstrated significant improvements in its loss per share and earnings per share compared to the previous year and the previous quarter. Despite revenue remaining unchanged, Baudax Bio Inc reported a substantial decrease in its net shortfall. This article aims to outline the facts and interpret these financial results.
1. Improving Financial Performance:
For the July to September 2023 period, Baudax Bio Inc managed to decrease its loss per share from $-2.47 to $-0.30 when compared to the same quarter last year, showcasing a remarkable improvement. Moreover, earnings per share saw significant growth from $-1.51 in the previous quarter to the current quarter.





 

Ironwood Pharmaceuticals Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com